Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Serum amyloid A impairs the antiinflammatory properties of HDL

  • Chang Yeop Han
  • , Chongren Tang
  • , Myriam E. Guevara
  • , Hao Wei
  • , Tomasz Wietecha
  • , Baohai Shao
  • , Savitha Subramanian
  • , Mohamed Omer
  • , Shari Wang
  • , Kevin D. O'Brien
  • , Santica M. Marcovina
  • , Thomas N. Wight
  • , Tomas Vaisar
  • , Maria C. De Beer
  • , Frederick C. De Beer
  • , William R. Osborne
  • , Keith B. Elkon
  • , Alan Chait

Producción científica: Articlerevisión exhaustiva

143 Citas (Scopus)

Resumen

HDL from healthy humans and lean mice inhibits palmitate-induced adipocyte inflammation; however, the effect of the inflammatory state on the functional properties of HDL on adipocytes is unknown. Here, we found that HDL from mice injected with AgNO3 fails to inhibit palmitate-induced inflammation and reduces cholesterol efflux from 3T3-L1 adipocytes. Moreover, HDL isolated from obese mice with moderate inflammation and humans with systemic lupus erythematosus had similar effects. Since serum amyloid A (SAA) concentrations in HDL increase with inflammation, we investigated whether elevated SAA is a causal factor in HDL dysfunction. HDL from AgNO3-injected mice lacking Saa1.1 and Saa2.1 exhibited a partial restoration of antiinflammatory and cholesterol efflux properties in adipocytes. Conversely, incorporation of SAA into HDL preparations reduced antiinflammatory properties but not to the same extent as HDL from AgNO3-injected mice. SAAenriched HDL colocalized with cell surface-associated extracellular matrix (ECM) of adipocytes, suggesting impaired access to the plasma membrane. Enzymatic digestion of proteoglycans in the ECM restored the ability of SAA-containing HDL to inhibit palmitate-induced inflammation and cholesterol efflux. Collectively, these findings indicate that inflammation results in a loss of the antiinflammatory properties of HDL on adipocytes, which appears to partially result from the SAA component of HDL binding to cell-surface proteoglycans, thereby preventing access of HDL to the plasma membrane.

Idioma originalEnglish
Páginas (desde-hasta)266-281
Número de páginas16
PublicaciónJournal of Clinical Investigation
Volumen126
N.º1
DOI
EstadoPublished - ene 4 2016

Nota bibliográfica

Funding Information:
C. Tang and S. Wang have equity in health care–related publicly traded companies. K.D. O’Brien has received a grant from Sanofi. S.M. Marcovina is a consultant to Denka, Japan, and Medtest, USA; holds a patent for an assay for lipoprotein(a); and has received a grant from Inventive Health Clinical LLC. F.C. de Beer is an inventor and holds a patent entitled “Compositions and methods for detecting and treating atherosclerosis.” K.B. Elkon has part ownership of a company called Resolve Therapeutics LLC. This work was supported in part by NIH grants HL092969, 094352, and DK-035816 and a Beginning Grant-in-Aid from the American Heart Association (to C.Y. Han). A. Chait was supported by a Grant-in-Aid from the American Heart Association.

Funding Information:
C. Tang and S. Wang have equity in health care?related publicly traded companies. K.D. O?Brien has received a grant from Sanofi. S.M. Marcovina is a consultant to Denka, Japan, and Medtest, USA; holds a patent for an assay for lipoprotein(a); and has received a grant from Inventive Health Clinical LLC. F.C. de Beer is an inventor and holds a patent entitled ?Compositions and methods for detecting and treating atherosclerosis.? K.B. Elkon has part ownership of a company called Resolve Therapeutics LLC. This work was supported in part by NIH grants HL092969, 094352, and DK-035816 and a Beginning Grant-in-Aid from the American Heart Association (to C.Y. Han). A. Chait was supported by a Grant-in-Aid from the American Heart Association.

Financiación

C. Tang and S. Wang have equity in health care–related publicly traded companies. K.D. O’Brien has received a grant from Sanofi. S.M. Marcovina is a consultant to Denka, Japan, and Medtest, USA; holds a patent for an assay for lipoprotein(a); and has received a grant from Inventive Health Clinical LLC. F.C. de Beer is an inventor and holds a patent entitled “Compositions and methods for detecting and treating atherosclerosis.” K.B. Elkon has part ownership of a company called Resolve Therapeutics LLC. This work was supported in part by NIH grants HL092969, 094352, and DK-035816 and a Beginning Grant-in-Aid from the American Heart Association (to C.Y. Han). A. Chait was supported by a Grant-in-Aid from the American Heart Association. C. Tang and S. Wang have equity in health care?related publicly traded companies. K.D. O?Brien has received a grant from Sanofi. S.M. Marcovina is a consultant to Denka, Japan, and Medtest, USA; holds a patent for an assay for lipoprotein(a); and has received a grant from Inventive Health Clinical LLC. F.C. de Beer is an inventor and holds a patent entitled ?Compositions and methods for detecting and treating atherosclerosis.? K.B. Elkon has part ownership of a company called Resolve Therapeutics LLC. This work was supported in part by NIH grants HL092969, 094352, and DK-035816 and a Beginning Grant-in-Aid from the American Heart Association (to C.Y. Han). A. Chait was supported by a Grant-in-Aid from the American Heart Association.

FinanciadoresNúmero del financiador
Inventive Health Clinical LLC
Resolve Therapeutics LLC
National Institutes of Health (NIH)094352, P30DK017047, DK-035816, P01HL092969
National Heart, Lung, and Blood Institute (NHLBI)T32HL007028
American the American Heart Association
Sanofi

    ASJC Scopus subject areas

    • General Medicine

    Huella

    Profundice en los temas de investigación de 'Serum amyloid A impairs the antiinflammatory properties of HDL'. En conjunto forman una huella única.

    Citar esto